Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atrial Flutter Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter

NCT01710150
View directory record Official record
Conditions
Typical Atrial Flutter, Risk Factors With Future Development of Atrial Flutter
Interventions
CTI ablation alone, CTI ablation and Pulmonary vein isolation (PVI)
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

NCT04213807
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo
Biological · Other
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)

NCT00984204
View directory record Official record
Conditions
Typical Atrial Flutter
Interventions
Therapy Cool Path Duo
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Sacramento, California • Kansas City, Kansas • Lexington, Kentucky + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Not applicable Interventional

AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

NCT06123130
View directory record Official record
Conditions
Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia
Interventions
Vectorcardiography (VECG)
Device
Lead sponsor
HeartBeam, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Atlanta, Georgia • Tucker, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

NCT03737838
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atrial fibrillation ablation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

NCT02132767
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone, DC-cardioversion, Rate Control
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational

Novel Cardiac Signal Processing System

NCT04112433
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
PURE EP 2
Device
Lead sponsor
BioSig Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126074
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Honolulu, Hawaii • Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational Results available

EnSite Precision Observational Study

NCT03260244
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
cardiac mapping and radiofrequency ablation procedure
Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Jul 21, 2026, 9:27 AM EDT
Not listed Not applicable Interventional

Ablation of Typical Right Atrial Flutter

NCT05755074
View directory record Official record
Conditions
Atrial Flutter
Interventions
Ablation through left arm, Ablation through femoral vein
Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation

NCT02524977
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Decision Support, Educational Intervention Only
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Clarification of Optimal Anticoagulation Through Genetics

NCT00839657
View directory record Official record
Conditions
Stroke, Venous Thrombosis, Atrial Fibrillation, Atrial Flutter
Interventions
Genotype-guided dosing algorithm for warfarin, Clinical-guided dosing algorithm for warfarin
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

NCT00126061
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 21, 2026, 9:27 AM EDT
Not listed No phase listed Observational

Dielectric Tissue Imaging in Cavotricuspid Isthmus Ablation

NCT04438395
View directory record Official record
Conditions
Atrial Fibrillation and Flutter
Interventions
Cardiac ablation via catheter
Device
Lead sponsor
EPD Solutions, A Philips Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter

NCT01439386
View directory record Official record
Conditions
Atrial Arrhythmia, Quality of Life
Interventions
Catheter ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational Results available

FREEZE-AFIB Post-Market Study

NCT05089877
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Surgical Ablation
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Hartford, Connecticut • New Haven, Connecticut • Evanston, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

NCT04118530
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Atrial Fibrillation, Atrial Flutter
Interventions
HSCT Patients
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational

Atrial Fibrillation/Flutter Outcome Risk Determination

NCT01138644
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 21, 2026, 9:27 AM EDT
Completed No phase listed Observational Results available

Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography

NCT02213666
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Intracardiac Imaging
Device
Lead sponsor
Elad Anter
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Phase 2Phase 3 Interventional

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

NCT00233441
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 21, 2026, 9:27 AM EDT
Active, not recruiting Early Phase 1 Interventional

Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation

NCT03929718
View directory record Official record
Conditions
AFib
Interventions
Spironolactone, No Spironolactone
Drug
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 21, 2026, 9:27 AM EDT
Recruiting No phase listed Observational

Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

NCT05014802
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Arrhythmia, Atrial Flutter, Atrial Tachycardia
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
40 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Covington, Louisiana • New Orleans, Louisiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study

NCT03720639
View directory record Official record
Conditions
Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter, Tachycardia, Stroke
Interventions
Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
Device
Lead sponsor
Sparrow Clinical Research Institute
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Lansing, Michigan • Traverse City, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 21, 2026, 9:27 AM EDT